Hims & Hers Health (HIMS) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Hims & Hers Health

NYSE•Healthcare•Drug Manufacturers - Specialty & Generic

$27.90-0.27(-0.01%)Pre-market

Market Cap

$6.46B

P/S

2.5x

P/B

19.9x

Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, Australia, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. The company was formerly known as Hims, Inc. and changed its name to Hims & Hers Health, Inc. in January 2021. The company was founded in 2017 and is based in San Francisco, California.

How this company scores

WeakMetricSide Score: 38/100

Strongest: Growth (14/25); weakest: Balance Sheet & Red Flags (5/25).

Profitability8/25

Growth14/25

Balance Sheet & Red Flags5/25

Cash & Earnings Quality11/25

Strengths

Growing revenueLong cash runwayConsistent growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 58.5x5y range 39.4x – 239.4x

Currently near its 7-quarter median.

P/S · 2.5x5y range 1.7x – 8.0x

Currently near its 20-quarter median.

P/B · 19.9x5y range 3.0x – 23.0x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

Operating margins dropped 192.2% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 3 quarters — monitor for earnings quality deterioration.

Price & Volume

Market Cap $6.46B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $2.58B
Q. Revenue: $753.21M
TTM EBITDA: $-39.20M
TTM Op. Income: $-154.52M
Q. Op. Income: $-97.19M
TTM Net Income: $-142.03M
Q. Net Income: $-86.29M
EPS: $-0.37
Shares Out.: $231.75M

$2.58B in TTM revenue grew 28.0% YoY, reaching $753.21M last quarter. TTM EBITDA of $-39.20M and TTM operating income of $-154.52M show growth is flowing through to the bottom line. However, net income is negative at $142.03M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 63.8%
EBITDA Margin: -9.0%
Op. Margin: -12.9%
Net Margin: -11.5%

Op. margin of -12.9% is down 17.8% YoY — costs are rising relative to revenue. Net margin at -11.5% and gross margin of 63.8% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has fallen for 5 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 2.5x
P/B Ratio: 19.9x

P/S of 2.5x and P/B of 19.9x. Over the past year, P/E is up 34% — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $3.63B
Cash: $609.81M
Long-Term Debt: $1.37B
Book Value: $324.07M
D/E Ratio: 4.2
Debt/EBITDA: N/A

With $3.63B in assets and $1.37B in long-term debt, D/E is 4.2and book value is $324.07M — elevated leverage, meaning significant financial risk in a downturn. Across the last 8 quarters, debt/equity has risen for 3 consecutive quarters — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-35.94M
TTM Free Cash Flow: $61.65M
FCF Margin: 2.4%
FCF / Net Income: -0.4

TTM FCF of $61.65M on $-35.94M in operating cash flow. The FCF / Net Income ratio of -0.4x means the business consumes cash — it is not yet self-funding. Across the last 8 quarters, free cash flow has risen for 2 consecutive quarters — an improving trend.